close
close

Curis will present at the upcoming healthcare conference in July 2024.

Curis will present at the upcoming healthcare conference in July 2024.

LEXINGTON, Mass., July 10, 2024 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will deliver a presentation at Jones Healthcare Seaside Summit 2024 on July 15, 2024 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time). A live webcast and archived replays will be available and can be accessed at Here or in the Events and Presentations section of the Curis website.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being tested in the Phase 1/2 TakeAim Lymphoma trial in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as monotherapy in the Phase 1/2 TakeAim Leukemia trial in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (hrMDS) with a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as first-line combination therapy with azacitidine and venetoclax in patients with AML. Emavusertib has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis has an exclusive license to emavusertib (CA-4948) through a 2015 collaboration with Aurigene. Curis has licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they will commercialize Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit the Curis website at www.curis.com

View original content to download media:

SOURCE Curis, Inc.


Company codes: NASDAQ-NMS:CRIS